James A. Fugate

TL;DR: This work generated highly purified human cardiomyocytes using a readily scalable system for directed differentiation that relies on activin A and BMP4, and identified a cocktail of pro-survival factors that limitsCardiomyocyte death after transplantation.

TL;DR: It is shown that hESC-CMs can be produced at a clinical scale (more than one billion cells per batch) and cryopreserved with good viability and can remuscularize substantial amounts of the infarcted monkey heart.

TL;DR: This work establishes a foundation for spatially controlled cardiac tissue engineering by providing discrete compartments for cardiomyocytes and stroma in a scaffold that enhances vascularization and integration while controlling the inflammatory response.

TL;DR: It is shown that transplantation of ∼750 million cryopreserved human embryonic stem cell–derived cardiomyocytes (hESC-CMs) enhances cardiac function in macaque monkeys with large myocardial infarctions and provides durable improvement in left ventricular function.

TL;DR: The results demonstrate the feasibility of generating cardiomyocytes from a urine sample and that urine-derived carduomyocytes retain characteristic features that might be further exploited for mechanistic studies and drug discovery.